Herbal-based therapeutics for diabetic patients with SARS-Cov-2 infection.
COVID-19
Cytokine storm
Diabetes
Herbal medication
Inflammation
Respiratory tract infection
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
26
07
2023
accepted:
26
01
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
epublish
Résumé
Human SARS Coronavirus-2 (SARS-CoV-2) has infected more than 170 million people worldwide, being responsible for about 3.5 million deaths so far. Despite ongoing investigations, there is still more to understand the mechanism of COVID-19 infection completely. However, it has been evidenced that SARS-CoV-2 can cause Coronavirus disease (COVID-19) notably in diabetic people. Approximately 35% of the patients who died of this disease had diabetes. A growing number of studies have evidenced that hyperglycemia is a significant risk factor for severe SARS-CoV-2 infection and plays a key role in COVID-19 mortality and diabetes comorbidity. The uncontrolled hyperglycemia can produce low-grade inflammation and impaired immunity-mediated cytokine storm that fail multiple organs and sudden death in diabetic patients with SARS-CoV-2 infection. More importantly, SARS-CoV-2 infection and interaction with ACE2 receptors also contribute to pancreatic and metabolic impairment. Thus, using of diabetes medications has been suggested to be beneficial in the better management of diabetic COVID-19 patients. Herbal treatments, as safe and affordable therapeutic agents, have recently attracted a lot of attention in this field. Accordingly, in this review, we intend to have a deep look into the molecular mechanisms of diabetic complications in SARS-CoV-2 infection and explore the therapeutic potentials of herbal medications and natural products in the management of diabetic COVID-19 patients based on recent studies and the existing clinical evidence.
Identifiants
pubmed: 38376656
doi: 10.1007/s11033-024-09291-1
pii: 10.1007/s11033-024-09291-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Guo W et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metab Res Rev 36(7):e3319
pubmed: 32233013
Imran M et al (2019) Kaempferol: a key emphasis to its anticancer potential. Molecules 24(12):2277
pubmed: 31248102
pmcid: 6631472
Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4:177
pubmed: 24454289
pmcid: 3887317
Khaerunnisa S et al (2020) Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints 2020:2020030226
Modak M et al (2007) Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 40(3):163–173
pubmed: 18398493
pmcid: 2275761
Saeedi P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843
pubmed: 31518657
Lima-Martínez MM et al (2021) COVID-19 and diabetes: a bidirectional relationship. Clin Investig Arterioscler 33(3):151–157
pubmed: 33303218
Al-kuraishy HM et al (2021) COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 8:644095
pubmed: 34124187
pmcid: 8189260
Sacks LJ et al (2020) Considerations for people with diabetes during the Coronavirus Disease (COVID-19) pandemic. Diabetes Res Clin Pract 166:108296
pubmed: 32623041
pmcid: 7332442
Li Y et al (2021) Follow-up study of pulmonary sequelae in discharged COVID-19 patients with diabetes or secondary hyperglycemia. Eur J Radiol 144:109997
pubmed: 34634534
pmcid: 8500791
Gęca T et al (2022) Increased risk of COVID-19 in patients with diabetes mellitus—current challenges in pathophysiology, treatment and prevention. Int J Environ Res Public Health 19(11):6555
pubmed: 35682137
pmcid: 9180541
Fernando SM, Cardinal P, Brindley PG (2017) Hypoxemic respiratory failure from acute respiratory distress syndrome secondary to leptospirosis. Case Rep Crit Care 2017:9062107
pubmed: 29158922
pmcid: 5660762
Reiterer M et al (2021) Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab 33(11):2174-2188.e5
pubmed: 34599884
pmcid: 8443335
Zhu L et al (2020) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing Type 2 diabetes. Cell Metab 31(6):1068-1077.e3
pubmed: 32369736
pmcid: 7252168
Sardu C et al (2020) Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 43(7):1408–1415
pubmed: 32430456
pmcid: 7305003
Barron E et al (2020) Associations of Type 1 and Type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 8(10):813–822
pubmed: 32798472
pmcid: 7426088
Cariou B et al (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8):1500–1515
pubmed: 32472191
pmcid: 7256180
Reshad RAI et al (2021) Diabetes in COVID-19 patients: challenges and possible management strategies. Egypt J Bronchol 15(1):53
Borges RC, Hohmann MS, Borghi SM (2021) Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. Int Rev Immunol 40(1–2):108–125
pubmed: 33191813
Alhuthali HM et al (2023) Neutrophilia and its correlation with increased inflammatory response in COVID-19 in diabetic and pre-diabetic patients. Eur J Inflamm 21:1–8
Han M et al (2021) Immunological characteristics in Type 2 diabetes mellitus among COVID-19 patients. Front Endocrinol (Lausanne) 12:596518
pubmed: 33776910
Pechlivani N, Ajjan RA (2018) Thrombosis and vascular inflammation in diabetes: mechanisms and potential therapeutic targets. Front Cardiovasc Med 5:1
pubmed: 29404341
pmcid: 5780411
Basra R et al (2022) What is the impact of microvascular complications of diabetes on severe COVID-19? Microvasc Res 140:104310
pubmed: 34979154
AlugantiNarasimhulu C, Singla DK (2022) Mechanisms of COVID-19 pathogenesis in diabetes. Am J Physiol Heart Circ Physiol 323(3):H403–H420
Pennathur S, Heinecke JW (2007) Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 7(4):257–264
pubmed: 17686400
Burgess JL et al (2021) Diabetic wound-healing science. Medicina 57(10):1072
pubmed: 34684109
pmcid: 8539411
Oropallo A et al (2021) Wound care during the COVID-19 pandemic: improving outcomes through the integration of telemedicine. J Wound Care 30(Sup2):S12–S17
pubmed: 33573492
Cheng Y et al (2020) Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv 2020.02.18.20023242
Khalili S et al (2021) Prevalence, risk factors and outcomes associated with acute kidney injury in patients hospitalized for COVID-19: a comparative study between diabetic and nondiabetic patients. J Diabetes Res 2021:6666086
pubmed: 33506050
pmcid: 7808817
D’Marco L et al (2020) Diabetic kidney disease and COVID-19: the crash of two pandemics. Front Med (Lausanne) 7:199
pubmed: 32435649
Abdulaziz Al-Muhanna F et al (2022) Impact of COVID-19 on kidney of diabetic patients. Medicina (Kaunas) 58(5):644
pubmed: 35630061
Vellanki P, Umpierrez GE (2021) Diabetic ketoacidosis risk during the COVID-19 pandemic. Lancet Diabetes Endocrinol 9(10):643–644
pubmed: 34481553
pmcid: 8412797
de Sá-Ferreira CO et al (2022) Diabetic ketoacidosis and COVID-19: what have we learned so far? Am J Physiol Endocrinol Metab 322(1):E44–E53
pubmed: 34779657
Hajifathalian K et al (2020) Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. Obesity (Silver Spring) 28(9):1606–1612
pubmed: 32470210
Kaur I et al (2022) A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic. Environ Sci Pollut Res Int 29(45):67685–67703
pubmed: 35933528
pmcid: 9362373
Bailey CJ, Gwilt M (2022) Diabetes, metformin and the clinical course of COVID-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol 13:784459
pubmed: 35370738
pmcid: 8964397
Khan F et al (2023) Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals. Cureus 15(3):e36005
pubmed: 37041898
pmcid: 10083655
Kwan AC et al (2023) Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 infection. JAMA Netw Open 6(2):e2255965
pubmed: 36787145
pmcid: 9929690
Kim HJ et al (2023) Safety of COVID-19 vaccines among patients with Type 2 diabetes mellitus: real-world data analysis. Diabetes Metab J 47(3):356–365
pubmed: 36872064
Lin X et al (2020) Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 10(1):14790
pubmed: 32901098
pmcid: 7478957
Sathish T et al (2021) Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab 47(2):101204
pubmed: 33129968
Lim S et al (2021) COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17(1):11–30
pubmed: 33188364
Wu KCH et al (2022) Shared genetic mechanism between type 2 diabetes and COVID-19 using pathway-based association analysis. Front Genet 13:1063519
pubmed: 36482905
pmcid: 9724785
Pouremamali A et al (2022) Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. Egypt J Med Hum Genet 23(1):1–10
D’Onofrio N et al (2021) Glycated ACE2 receptor in diabetes: open door for SARS-CoV-2 entry in cardiomyocyte. Cardiovasc Diabetol 20(1):99
pubmed: 33962629
pmcid: 8104461
Pinchera B et al (2022) Diabetes and COVID-19: the potential role of mTOR. Diabetes Res Clin Pract 186:109813
pubmed: 35248653
pmcid: 8891119
Calvisi SL et al (2021) Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. Metabolism 123:154845
pubmed: 34364927
pmcid: 8340557
Beyerstedt S, Casaro EB, Rangel B (2021) COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 40(5):905–919
pubmed: 33389262
pmcid: 7778857
Elshafei A et al (2021) RAAS, ACE2 and COVID-19; a mechanistic review. Saudi J Biol Sci 28(11):6465–6470
pubmed: 34305426
pmcid: 8270731
Memon B, Abdelalim EM (2021) ACE2 function in the pancreatic islet: implications for relationship between SARS-CoV-2 and diabetes. Acta Physiol (Oxf) 233(4):e13733
pubmed: 34561952
Varghese E et al (2021) Diabetes and coronavirus (SARS-CoV-2): molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathog 17(6):e1009634
pubmed: 34157054
pmcid: 8219155
Berbudi A et al (2020) Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 16(5):442–449
pubmed: 31657690
pmcid: 7475801
Dallavalasa S et al (2023) COVID-19: diabetes perspective—pathophysiology and management. Pathogens 12(2):184
pubmed: 36839456
pmcid: 9967788
Shin J et al (2022) SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism 133:155236
pubmed: 35688210
pmcid: 9173833
Karam BS et al (2021) mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol 93(4):1843–1846
pubmed: 33314219
Ganesan SK et al (2020) Increased mortality of COVID-19 infected diabetes patients: role of furin proteases. Int J Obes 44(12):2486–2488
Brouwers B et al (2020) Furin controls β cell function via mTORC1 signaling. bioRxiv 2020.04.09.027839
Kurdi A, Martinet W, De Meyer GR (2018) mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation 102(2S):S44–S46
pubmed: 28230638
Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol 5(3):150–159
Hariyanto TI, Kurniawan A (2020) Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr Clin Res Rev 14(5):1463–1465
Hashemi SMA et al (2021) Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Arch Virol 166:2089–2108
pubmed: 33934196
pmcid: 8088757
Sen S et al (2021) Diabetes mellitus and COVID-19: understanding the association in light of current evidence. World J Clin Cases 9(28):8327
pubmed: 34754842
pmcid: 8554438
Sayed S (2021) COVID-19 and diabetes; possible role of polymorphism and rise of telemedicine. Prim Care Diabetes 15(1):4–9
pubmed: 32912711
Faridzadeh A et al (2022) The role of ACE1 I/D and ACE2 polymorphism in the outcome of Iranian COVID-19 patients: a case–control study. Front Genet 13:955965
pubmed: 36134024
pmcid: 9483011
Balmeh N et al (2020) Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inform Med Unlocked 20:100407
pubmed: 32835083
pmcid: 7411426
Yusuf AP et al (2022) Herbal medications and natural products for patients with covid-19 and diabetes mellitus: potentials and challenges. Phytomed Plus 2(3):100280
pubmed: 35463625
pmcid: 9014648
Chowdhury P (2021) In silico investigation of phytoconstituents from Indian medicinal herb ‘Tinospora cordifolia (giloy)’ against SARS-CoV-2 (COVID-19) by molecular dynamics approach. J Biomol Struct Dyn 39(17):6792–6809
pubmed: 32762511
Panchamoorthy R, Prabhakar P (2022) Mucormycosis, a post-COVID infection: possible adjunctive herbal therapeutics for the realigning of impaired immune-metabolism in diabetic subjects. Herba Pol 68(2):86–98
Aucoin M et al (2021) A systematic review on the effects of Echinacea supplementation on cytokine levels: is there a role in COVID-19? Metab Open 11:100115
Aucoin M et al (2020) The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: a rapid review. Adv Integr Med 7(4):203–217
pubmed: 32837894
pmcid: 7395221
Delorme D, Miller SC (2005) Dietary consumption of Echinacea by mice afflicted with autoimmune (Type I) diabetes: effect of consuming the herb on hemopoietic and immune cell dynamics. Autoimmunity 38(6):453–461
pubmed: 16278152
Behl T, Kotwani A (2016) Proposed mechanisms of Terminalia catappa in hyperglycaemia and associated diabetic complications. J Pharm Pharmacol 69(2):123–134
pubmed: 28000229
Akhtar MT et al (2016) Anti-diabetic activity and metabolic changes induced by Andrographis paniculata plant extract in obese diabetic rats. Molecules 21(8):1026
pubmed: 27517894
pmcid: 6273188
Siripongboonsitti T et al (2023) Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: a double-blind, randomized, placebo-controlled study (APFaVi trial). Phytomedicine 119:155018
pubmed: 37625206
Kashyap S et al (2021) Uncurtaining the effect of COVID-19 in diabetes mellitus: a complex clinical management approach. Environ Sci Pollut Res 28(27):35429–35436
Silveira D et al (2020) COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Front Pharmacol 11:581840
pubmed: 33071794
pmcid: 7542597
Bafandeh S et al (2023) Natural products as a potential source of promising therapeutics for COVID-19 and viral diseases. Evid Based Complement Altern Med 2023:5525165
Sharma N et al (2022) Therapeutic options for the SARS-CoV-2 virus: is there a key in herbal medicine? Nat Prod Commun 17(9):1934578X221126303
Gomez CR et al (2021) Therapeutic intervention of COVID-19 by natural products: a population-specific survey directed approach. Molecules 26(4):1191
pubmed: 33672163
pmcid: 7927139